Hemp THC Under Schedule 1: Legal Status and State Regulation Conflicts

Executive Summary

The legal status of hemp-derived THC products under federal Schedule I classification creates a fundamental conflict between the 2018 Farm Bill's hemp legalization and the Controlled Substances Act. While the Agricultural Improvement Act of 2018 removed hemp—defined as cannabis containing no more than 0.3% delta-9 THC by dry weight—from Schedule I, the proliferation of intoxicating hemp-derived cannabinoids including delta-8 THC, delta-10 THC, THC-O, and THCA has exposed critical gaps in federal oversight. State-regulated hemp THC businesses operate in a legal gray zone where federal drug scheduling, agricultural law, and state commerce regulations intersect without clear resolution. The Drug Enforcement Administration maintains that synthetically derived THC isomers remain Schedule I controlled substances regardless of their hemp origin, while industry advocates argue the 2018 Farm Bill's broad definition of "hemp" encompasses all derivatives, extracts, and cannabinoids from compliant plants. This conflict affects thousands of retail locations, hundreds of millions in annual sales, and millions of consumers who access these products in states without adult-use cannabis programs.

Why This Matters

The hemp THC scheduling question determines whether a multi-billion dollar industry operates legally or faces federal enforcement action. According to industry analysis, the hemp-derived cannabinoid market generated approximately $2.8 billion in retail sales during 2025, with delta-8 THC products representing the largest segment. More than 15,000 retail locations across the United States sell hemp-derived THC products, including gas stations, smoke shops, CBD retailers, and online vendors. The stakeholder impact extends across multiple sectors. Hemp farmers who cultivated approximately 54,000 acres in 2025 depend on demand for cannabinoid extraction beyond traditional CBD products. Processors and manufacturers have invested tens of millions in extraction equipment, isomerization technology, and quality control infrastructure specifically for hemp-derived THC production. Retailers face inventory risk and potential criminal liability if federal interpretation shifts. State regulators in the 23 states that have explicitly regulated or restricted hemp THC products must reconcile their frameworks with federal scheduling decisions. Consumer access represents the most significant impact. In states without adult-use cannabis programs, hemp-derived THC products provide the only legal access to intoxicating cannabinoids for adults. An estimated 8-12 million Americans purchased hemp THC products in 2025, many seeking alternatives to alcohol, pharmaceutical sleep aids, or anxiety medications. Medical patients in restrictive states use hemp-derived cannabinoids when they cannot access state medical cannabis programs due to qualifying condition limitations or registry requirements. The federal revenue implications are substantial. The Internal Revenue Service's application of 26 U.S.C. § 280E—which prohibits business expense deductions for trafficking in Schedule I or II substances—to hemp THC businesses could generate hundreds of millions in additional tax revenue, but also threatens business viability. The Department of Agriculture's regulatory authority over hemp cultivation hinges on maintaining the Schedule I exemption the 2018 Farm Bill created.

Background and History

The Controlled Substances Act and Original Cannabis Scheduling

Cannabis was placed in Schedule I of the Controlled Substances Act in 1970 without scientific review, establishing the foundation for 50 years of federal prohibition. The Controlled Substances Act, codified at 21 U.S.C. § 801 et seq., created five schedules of controlled substances based on medical utility, abuse potential, and safety. Schedule I designation requires three findings: high potential for abuse, no currently accepted medical use in treatment in the United States, and lack of accepted safety for use under medical supervision. The Act defined "marihuana" at 21 U.S.C. § 802(16) to mean "all parts of the plant Cannabis sativa L., whether growing or not; the seeds thereof; the resin extracted from any part of such plant; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds or resin." This definition explicitly excluded "the mature stalks of such plant, fiber produced from such stalks, oil or cake made from the seeds of such plant, any other compound, manufacture, salt, derivative, mixture, or preparation of such mature stalks (except the resin extracted therefrom), fiber, oil, or cake, or the sterilized seed of such plant which is incapable of germination." The Drug Enforcement Administration was created in 1973 to enforce the Controlled Substances Act, consolidating drug enforcement functions from multiple agencies. For decades, the DEA made no practical distinction between hemp and marijuana, treating all cannabis as Schedule I regardless of THC content.

The 2014 Farm Bill and Pilot Programs

The Agricultural Act of 2014 created the first federal hemp legalization pathway through state-supervised pilot programs. Section 7606 of the 2014 Farm Bill, codified at 7 U.S.C. § 5940, authorized institutions of higher education and state departments of agriculture to grow industrial hemp for research purposes in states that permitted hemp cultivation. The provision defined industrial hemp as "the plant Cannabis sativa L. and any part of such plant, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." Between 2014 and 2018, 41 states established hemp pilot programs under this authority. Kentucky, Colorado, Oregon, and North Carolina emerged as leading hemp cultivation states. The pilot programs focused primarily on fiber, grain, and CBD production. Total U.S. hemp acreage grew from approximately 9,000 acres in 2016 to more than 78,000 acres in 2018. The 2014 Farm Bill did not remove hemp from the Controlled Substances Act's definition of marijuana. Hemp remained technically Schedule I, with pilot program participants operating under a specific statutory exemption. This created ongoing confusion about the legal status of hemp-derived products in interstate commerce.

The 2018 Farm Bill and Full Hemp Legalization

The Agricultural Improvement Act of 2018 removed hemp from Schedule I entirely, creating the legal foundation for the current hemp industry. Senate Majority Leader Mitch McConnell championed the hemp provisions, which were included in the final bill signed by President Donald Trump on December 20, 2018. Section 10113 of the 2018 Farm Bill amended the Agricultural Marketing Act of 1946 to add Subtitle G—Hemp Production. Section 297A defined hemp as "the plant Cannabis sativa L. and any part of that plant, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, whether growing or not, with a delta-9 tetrahydrocannabinol concentration of not more than 0.3 percent on a dry weight basis." This definition explicitly included "all derivatives, extracts, cannabinoids"—language that would become central to later disputes. Section 12619 of the 2018 Farm Bill amended 21 U.S.C. § 802(16) to exclude hemp from the Controlled Substances Act's definition of marijuana. The amendment stated that the term "marihuana" does not include "hemp, as defined in section 297A of the Agricultural Marketing Act of 1946." This statutory change removed hemp from Schedule I without requiring DEA rulemaking or rescheduling procedures. The 2018 Farm Bill transferred primary regulatory authority over hemp cultivation from the DEA to the U.S. Department of Agriculture. The USDA was directed to establish a federal hemp production program and approve state and tribal hemp production plans. The legislation maintained the 0.3% delta-9 THC threshold, required testing within 15 days of harvest, and established procedures for handling non-compliant plants.

USDA Hemp Regulations and Implementation

The USDA published interim final hemp production rules on October 31, 2019, establishing the regulatory framework for cultivation but avoiding cannabinoid product issues. The Establishment of a Domestic Hemp Production Program interim final rule, published at 84 Fed. Reg. 58522, created 7 C.F.R. Part 990. The regulations specified sampling procedures, testing protocols, disposal requirements for non-compliant plants, and licensing standards. The USDA rules established that hemp must be tested for total THC—meaning delta-9 THC plus delta-9 THCA multiplied by 0.877 (the conversion factor for decarboxylation). Plants testing above 0.3% total THC must be destroyed. The regulations created a 0.5% negligence threshold—plants testing between 0.3% and 0.5% total THC could be remediated or destroyed without penalty if the exceedance was unintentional. The USDA received more than 4,500 comments on the interim final rule. Industry stakeholders objected to the total THC testing requirement, the 15-day harvest window, and DEA background check requirements for license applicants. The USDA published a final rule on January 19, 2021, at 86 Fed. Reg. 5596, maintaining most provisions of the interim rule with minor modifications. Critically, the USDA regulations focused exclusively on cultivation and made no determinations about the legal status of hemp-derived cannabinoid products. The agency stated it lacked authority to regulate hemp products in commerce, deferring to the FDA for consumables and the DEA for controlled substances questions.

The Rise of Delta-8 THC and Hemp-Derived Intoxicants

Beginning in 2019, manufacturers began producing delta-8 THC from CBD through isomerization, creating the first widely available hemp-derived intoxicant. Delta-8 THC is a naturally occurring cannabinoid found in cannabis in trace amounts, typically less than 0.1% by dry weight. Chemists discovered that CBD isolate derived from hemp could be converted to delta-8 THC through acid-catalyzed isomerization using reagents such as hydrochloric acid, sulfuric acid, or Lewis acids. The delta-8 THC market exploded in 2020 and 2021. Products appeared in gas stations, smoke shops, and CBD retailers nationwide. Manufacturers marketed delta-8 as "legal THC" or "diet weed," emphasizing its hemp origin and the 2018 Farm Bill's legalization of hemp derivatives. Retail sales of delta-8 products reached an estimated $2 billion in 2021. The delta-8 phenomenon prompted immediate regulatory response. The DEA addressed delta-8 THC obliquely in an August 21, 2020 interim final rule on hemp implementation. In response to public comments, the DEA stated: "All synthetically derived tetrahydrocannabinols remain schedule I controlled substances." The agency clarified that "for synthetically derived THC, the concentration of delta-9 THC is not a determining factor in whether the material is a controlled substance. All synthetically derived THC remains schedule I controlled substances." This statement created immediate controversy. Industry advocates argued that delta-8 THC derived from hemp CBD through isomerization was a "hemp derivative" explicitly legalized by the 2018 Farm Bill. The DEA countered that chemical conversion constituted "synthetic derivation," distinguishing it from naturally extracted cannabinoids.

Expansion to Other Hemp-Derived Cannabinoids

Following delta-8 THC's commercial success, manufacturers introduced delta-10 THC, THC-O acetate, HHC, and THCP products between 2021 and 2024. Each new cannabinoid followed a similar pattern: chemists identified a minor cannabinoid or THC analog, developed a synthesis pathway from hemp-derived CBD or other cannabinoids, and manufacturers brought products to market emphasizing hemp origin and federal legality. Delta-10 THC, another THC isomer, appeared in late 2020. Hexahydrocannabinol (HHC), a hydrogenated form of THC, gained market share in 2021 and 2022. THC-O acetate, an acetylated prodrug of THC, emerged in 2021 but faced DEA scrutiny in 2023. Tetrahydrocannabiphorol (THCP), a naturally occurring cannabinoid with higher CB1 receptor affinity than delta-9 THC, entered the market in 2022. The DEA issued a letter on February 13, 2023, stating that THC-O acetate does not occur naturally in the cannabis plant and is therefore a controlled substance analog under 21 U.S.C. § 813. This marked the first time the agency explicitly invoked the Federal Analogue Act against a hemp-derived cannabinoid. The letter stated: "Delta-9-THCO and delta-8-THCO do not occur naturally in the cannabis plant and can only be obtained synthetically, and therefore do not fall under the definition of hemp."

THCA Flower and the Latest Legal Challenge

Beginning in 2023, hemp businesses began selling high-THCA flower that converts to delta-9 THC when heated, creating products functionally identical to marijuana. Tetrahydrocannabinolic acid (THCA) is the acidic precursor to delta-9 THC found in raw cannabis. When heated through smoking, vaping, or cooking, THCA decarboxylates to delta-9 THC through loss of a carboxyl group. Cannabis plants produce THCA, not delta-9 THC, in their trichomes. The 0.3% threshold in the 2018 Farm Bill and USDA regulations specifically references delta-9 THC concentration, not total THC or THCA. Hemp breeders developed cultivars that test below 0.3% delta-9 THC but contain 15-25% THCA—concentrations comparable to marijuana flower. High-THCA hemp flower creates the most direct challenge to the distinction between hemp and marijuana. When smoked, a product containing 20% THCA and 0.2% delta-9 THC produces intoxicating effects indistinguishable from marijuana containing 20% delta-9 THC. Retailers sell THCA flower in states without adult-use cannabis programs, often in packaging identical to marijuana products. The THCA flower phenomenon has prompted the most aggressive state-level responses. Between 2023 and 2025, at least 14 states banned or restricted THCA flower sales specifically, separate from other hemp THC products. Law enforcement agencies have expressed concern that THCA flower is indistinguishable from marijuana in field testing and visual inspection.

Key Players

Drug Enforcement Administration

The DEA maintains that synthetically derived THC isomers remain Schedule I controlled substances regardless of their hemp origin. The agency's position, articulated in the August 2020 interim final rule and subsequent guidance documents, distinguishes between naturally extracted cannabinoids and those produced through chemical synthesis or conversion. DEA Administrator Anne Milgram testified before Congress in March 2024 that "the proliferation of intoxicating hemp products was not the intent of the 2018 Farm Bill" and that the agency was evaluating enforcement options. The DEA has not initiated widespread enforcement actions against hemp THC businesses, focusing instead on regulatory clarification and state coordination. The agency's Diversion Control Division has issued warning letters to specific manufacturers but has not pursued criminal prosecutions. This enforcement restraint reflects resource constraints, conflicting legal interpretations, and political sensitivity around hemp policy.

U.S. Department of Agriculture

The USDA regulates hemp cultivation but explicitly disclaims authority over hemp-derived products. The agency's hemp production program focuses on pre-harvest testing, licensing, and ensuring plants comply with the 0.3% delta-9 THC threshold. USDA officials have stated in public forums that questions about post-harvest processing, cannabinoid conversion, and product legality fall outside their statutory mandate. Agriculture Secretary Tom Vilsack addressed hemp THC products in a July 2024 speech at the National Hemp Association conference, stating: "The 2018 Farm Bill legalized hemp cultivation, not intoxicating products. Congress needs to provide clarity on what products are permissible." The USDA has not proposed regulatory changes to address hemp-derived intoxicants, maintaining that such authority rests with the DEA and FDA.

Food and Drug Administration

The FDA regulates hemp-derived cannabinoid products as food additives, dietary supplements, or drugs depending on their marketing claims. The agency has maintained since 2018 that CBD and other cannabinoids cannot be added to food or marketed as dietary supplements without FDA approval. The FDA has issued warning letters to hundreds of companies making unapproved health claims about CBD products. Regarding intoxicating hemp cannabinoids, the FDA has focused on safety concerns rather than scheduling questions. The agency published a statement in May 2023 warning consumers about delta-8 THC products, citing adverse event reports and concerns about contamination from the isomerization process. The FDA has not approved any hemp-derived THC products for any use.

Hemp Industry Advocates

The U.S. Hemp Roundtable, National Hemp Association, and Hemp Industries Association argue that the 2018 Farm Bill's language encompasses all hemp derivatives. These trade organizations represent hemp farmers, processors, and product manufacturers. Their legal position emphasizes that Congress explicitly included "all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers" in the hemp definition. Jonathan Miller, general counsel for the U.S. Hemp Roundtable, has stated in multiple legal analyses that "if a cannabinoid is derived from a hemp plant that tests compliant at harvest, that cannabinoid is legal hemp under federal law, regardless of subsequent processing." Industry advocates distinguish between "synthetic cannabinoids" created entirely through chemical synthesis without plant material and "hemp-derived cannabinoids" that begin with plant-extracted CBD or other compounds. The industry has proposed federal legislation to clarify hemp product standards. The Hemp and Hemp-Derived Consumer Products Act, introduced in 2024, would establish THC serving size limits, testing requirements, and age restrictions while affirming that hemp-derived intoxicating products are legal.

State Regulators

State responses to hemp THC products range from explicit legalization with regulation to complete prohibition. States have taken divergent approaches based on their existing cannabis policies, public health concerns, and industry lobbying. Colorado became the first state to comprehensively regulate hemp-derived THC products in 2022. The state's Hemp and Hemp Product Regulation Act established serving size limits (2mg delta-9 THC per serving, 10mg per package for non-edible products), testing requirements, and licensing for manufacturers and retailers. Colorado's approach treats hemp THC products as a distinct category from both marijuana and non-intoxicating hemp products. Oregon passed legislation in 2023 requiring all intoxicating hemp products to be sold through the state's existing marijuana retail system. The law effectively eliminated the separate hemp THC market by subjecting these products to the same regulations, testing, and taxation as marijuana. Texas has maintained that delta-8 THC and other intoxicating hemp cannabinoids are controlled substances under state law, despite hemp legalization. The Texas Department of State Health Services added delta-8 and delta-9 THC isomers to the state's controlled substances schedule in 2021. Industry lawsuits challenging this determination remain in litigation as of 2025.

Legal and Regulatory Framework

The Controlled Substances Act Scheduling Criteria

Schedule I classification under 21 U.S.C. § 812 requires findings of high abuse potential, no accepted medical use, and lack of safety under medical supervision. The Attorney General, acting through the DEA, has authority to add, remove, or reschedule substances through rulemaking under 21 U.S.C. § 811. The process requires consideration of eight factors: actual or relative potential for abuse; scientific evidence of pharmacological effect; current scientific knowledge; history and current pattern of abuse; scope, duration, and significance of abuse; risk to public health; psychic or physiological dependence liability; and whether the substance is an immediate precursor of a controlled substance. The Controlled Substances Act's definition of marijuana at 21 U.S.C. § 802(16) was amended by the 2018 Farm Bill to exclude hemp. However, the Act's definition of THC at 21 C.F.R. § 1308.11(d)(31) lists "Tetrahydrocannabinols" as a Schedule I substance, with a note stating "synthetic equivalents of the substances contained in the plant" are controlled.

The Federal Analogue Act

The Controlled Substance Analogue Enforcement Act of 1986, codified at 21 U.S.C. § 813, treats chemical analogues of Schedule I substances as Schedule I substances when intended for human consumption. The Act defines a controlled substance analogue as a substance with a chemical structure substantially similar to a Schedule I or II substance, or with a stimulant, depressant, or hallucinogenic effect substantially similar to a Schedule I or II substance. The DEA invoked the Federal Analogue Act in its February 2023 letter regarding THC-O acetate. The agency could potentially apply this statute to other hemp-derived THC analogues such as HHC or THCP. However, the Analogue Act requires that the substance be "intended for human consumption," creating potential defenses for manufacturers who label products as "not for human consumption" or for research purposes.

The 2018 Farm Bill's Hemp Definition

Section 297A of the Agricultural Marketing Act of 1946, as added by the 2018 Farm Bill, defines hemp to include "all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers." This expansive language forms the basis of industry arguments that chemically converted cannabinoids remain legal hemp. The statute contains no limitation based on processing method, chemical conversion, or intoxicating effect. The hemp definition's 0.3% delta-9 THC threshold applies "on a dry weight basis" and does not specify whether it applies only to plant material or also to extracts and finished products. The USDA regulations interpret this threshold as applying to pre-harvest plant testing. No federal regulation explicitly addresses THC concentration limits in post-harvest hemp extracts or finished products.

The Agricultural Improvement Act's Savings Clause

Section 10114 of the 2018 Farm Bill preserved FDA authority over hemp-derived products, stating that nothing in the hemp provisions affects FDA's authority under the Federal Food, Drug, and Cosmetic Act. This savings clause means that even if hemp-derived cannabinoids are not controlled substances, they remain subject to FDA regulation as food additives, dietary supplements, cosmetics, or drugs depending on their intended use and marketing claims. The FDA has interpreted this authority to prohibit adding CBD or other cannabinoids to food or dietary supplements without agency approval. The FDA approved one CBD drug product, Epidiolex, for treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome in 2018. This approval complicates the regulatory pathway for other CBD products under the FDA's drug exclusion rule.

State-Level Hemp THC Regulations

At least 23 states have enacted specific regulations addressing hemp-derived intoxicating cannabinoids as of 2025. These regulations fall into several categories: comprehensive regulatory frameworks, prohibition, incorporation into existing marijuana programs, and age restrictions with labeling requirements. States with comprehensive hemp THC regulations include Colorado, Minnesota, Vermont, and Virginia. These states have established serving size limits (typically 2-5mg delta-9 THC per serving), testing requirements for potency and contaminants, labeling standards, age restrictions (21+), and licensing requirements for manufacturers and retailers. States that have prohibited hemp-derived intoxicating cannabinoids include Alaska, Arizona, Arkansas, Delaware, Idaho, Iowa, Montana, Nevada, New York, North Dakota, Rhode Island, Utah, and Washington. These states have either explicitly scheduled delta-8 THC and related compounds as controlled substances or interpreted their existing controlled substances laws to include all THC isomers regardless of source.

State-by-State Breakdown

California

California prohibits hemp-derived intoxicating cannabinoids from being sold outside the state's licensed marijuana system. Assembly Bill 45, signed in October 2023, banned the sale of hemp products containing "detectable amounts of THC" through non-cannabis retail channels. The law requires all intoxicating hemp products to be sold through licensed cannabis retailers and tested according to cannabis regulations. Possession limits align with marijuana law: 28.5 grams of flower or 8 grams of concentrate for adults 21 and over. Effective date was January 1, 2024. The law created a pathway for existing hemp THC businesses to transition into the regulated cannabis market through a temporary licensing process.

Colorado

Colorado established the nation's first comprehensive regulatory framework for hemp-derived THC products in 2022. House Bill 22-1317 created serving size limits of 2mg delta-9 THC per serving and 10mg per package for edibles, with higher limits for non-edible products. The law requires testing for potency, pesticides, heavy metals, and microbial contaminants. Retailers must obtain a regulated hemp food establishment license. Products must be sold in child-resistant packaging with warning labels. Age restriction is 21 and over. The Colorado Department of Public Health and Environment oversees the program. Total market size reached approximately $180 million in 2024.

Florida

Florida permits hemp-derived THC products with minimal state-level regulation beyond the 2018 Farm Bill requirements. The state has not enacted specific legislation restricting delta-8 THC or other hemp cannabinoids. The Florida Department of Agriculture and Consumer Services regulates hemp cultivation but has not issued rules governing hemp-derived intoxicating products. Age restrictions vary by retailer policy. No serving size limits or testing requirements beyond voluntary industry standards. The absence of state marijuana legalization has made Florida one of the largest hemp THC markets, with estimated 2024 sales exceeding $400 million.

Minnesota

Minnesota legalized hemp-derived THC edibles with serving size limits in 2022, then transitioned to full adult-use cannabis legalization in 2023. House File 4065, passed in 2022, allowed edible hemp products containing up to 5mg THC per serving and 50mg per package. The law required testing, labeling, and age restrictions (21+). Following passage of adult-use cannabis legalization in 2023, the state maintained separate regulatory pathways for hemp-derived and marijuana-derived products. The Office of Cannabis Management oversees both programs. Hemp THC products can be sold in broader retail channels than marijuana products, creating a two-tier market.

New York

New York banned the sale of hemp-derived cannabinoid products containing THC outside the licensed cannabis program in 2023. The state Office of Cannabis Management issued emergency regulations in September 2023 prohibiting the sale of "any cannabinoid hemp product for adult use" except through licensed cannabis retailers. The regulations defined cannabinoid hemp products as those containing "any amount of cannabinoids" intended to induce intoxication. Existing hemp CBD products without intoxicating cannabinoids remain legal in general retail. Possession limits follow marijuana law: 3 ounces of flower for adults 21 and over. The ban followed proliferation of unlicensed hemp THC retailers that competed with the state's licensed cannabis market.

Ohio

Ohio permits hemp-derived THC products under the 2018 Farm Bill without additional state restrictions as of 2025. The state legalized adult-use marijuana through a ballot initiative in November 2023, with sales beginning in 2024. However, Ohio has not integrated hemp-derived THC products into the marijuana regulatory framework. The Ohio Department of Agriculture regulates hemp cultivation. No state law explicitly addresses delta-8 THC or other hemp-derived intoxicants. Age restrictions and product standards vary by retailer. The parallel markets for marijuana and hemp THC products create regulatory confusion and competitive tension.

Texas

Texas maintains that delta-8 THC and similar hemp-derived intoxicants are controlled substances under state law despite ongoing litigation. The Texas Department of State Health Services added "delta-8 THC, delta-9 THC, and other tetrahydrocannabinols" to the state's Schedule I in October 2021. Industry plaintiffs filed suit arguing the scheduling violated the 2019 state hemp law that adopted the 2018 Farm Bill's hemp definition. A Travis County district court issued a temporary injunction in February 2022 preventing enforcement. The case remains in appellate litigation. Hemp THC products remain widely available pending final resolution. Texas does not have a legal marijuana program, making hemp-derived products the only legal access to THC for most residents.

Oregon

Oregon requires all intoxicating hemp products to be sold through the state's licensed marijuana retail system. House Bill 3000, passed in 2023, defined "adult use hemp cannabinoid" as any hemp product intended to induce intoxication. The law requires these products to be sold only by Oregon Liquor and Cannabis Commission-licensed retailers, tested according to marijuana standards, and taxed at marijuana rates. Serving size limits align with marijuana edible regulations: 5mg THC per serving, 50mg per package. The law effectively eliminated the separate hemp THC market by subjecting these products to identical regulations as marijuana. Implementation began January 1, 2024.

Market and Business Implications

Market Size and Growth Trajectory

The hemp-derived THC market generated approximately $2.8 billion in retail sales during 2025, with growth constrained by state-level restrictions. Market research firm Brightfield Group estimated the hemp THC segment grew from $1.2 billion in 2021 to $2.8 billion in 2025, representing a compound annual growth rate of 23%. Delta-8 THC products accounted for approximately 60% of sales, with THCA flower representing 25% and other cannabinoids comprising 15%. The market has shifted geographically as states implemented restrictions. Florida, Texas, Georgia, Tennessee, and North Carolina represented the five largest state markets in 2025, collectively accounting for 45% of national sales. These states lack adult-use marijuana programs, making hemp-derived products the primary legal access to intoxicating cannabinoids. Growth projections for 2026-2028 vary widely depending on federal regulatory outcomes. Optimistic scenarios project continued 15-20% annual growth if federal agencies maintain enforcement restraint. Pessimistic scenarios anticipate market contraction of 30-50% if the DEA initiates enforcement actions or Congress amends the 2018 Farm Bill to restrict intoxicating hemp products.

Multi-State Operator Response

Licensed marijuana multi-state operators have largely avoided the hemp THC market due to regulatory risk and competitive concerns. Major MSOs including Curaleaf, Trulieve, Green Thumb Industries, and Cresco Labs have not entered the hemp-derived cannabinoid space despite its revenue potential. These companies cite concerns about federal enforcement risk, state licensing implications, and brand reputation. Some MSOs have advocated for state-level restrictions on hemp THC products, arguing they create unfair competition for licensed marijuana businesses that face higher regulatory costs, testing requirements, and tax burdens. The Cannabis Trade Federation and other industry groups representing licensed operators have supported legislation to bring hemp intoxicants under marijuana regulatory frameworks. A small number of cannabis companies have launched separate hemp-derived product lines through subsidiary entities. These operators maintain corporate separation to insulate their licensed marijuana operations from potential federal enforcement against hemp THC businesses.

Wholesale Pricing and Supply Chain Economics

Wholesale pricing for hemp-derived cannabinoids has declined 60-70% since 2021 due to oversupply and manufacturing efficiency improvements. Delta-8 THC distillate traded at $1,200-1,500 per kilogram in early 2021, falling to $350-450 per kilogram by late 2025. THCA flower wholesale prices ranged from $200-400 per pound in 2025, compared to $600-800 per pound in 2023. The price compression reflects several factors: increased manufacturing capacity, improved isomerization efficiency, hemp biomass oversupply, and competitive pressure from state-level restrictions reducing market size. Manufacturers have responded by introducing higher-potency products, novel cannabinoids, and value-added formulations to maintain margins. Supply chain economics favor vertically integrated operators who control hemp cultivation, extraction, cannabinoid conversion, and product manufacturing. Companies operating only at the retail or distribution level face margin pressure from wholesale price volatility and inventory risk from potential regulatory changes.

Tax Treatment and 280E Implications

The Internal Revenue Service's application of 26 U.S.C. § 280E to hemp THC businesses remains unresolved, creating significant tax uncertainty. Section 280E prohibits businesses from deducting ordinary business expenses if they traffic in Schedule I or II controlled substances. The provision has been applied to state-licensed marijuana businesses since the 1980s, resulting in effective tax rates of 40-70%. Hemp businesses have generally treated themselves as exempt from 280E based on hemp's removal from the Controlled Substances Act. However, if the DEA's position that synthetically derived THC remains Schedule I is upheld, hemp THC businesses could face retroactive 280E liability. The IRS has not issued formal guidance on this question. Tax practitioners advise hemp THC businesses to maintain detailed records separating non-int